• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

METHIMAZOLE Drug Record

  • Summary
  • Interactions
  • Claims
  • METHIMAZOLE chembl:CHEMBL1515 ApprovedImmunotherapy

    Alternate Names:

    METHIMAZOLE
    TAPAZOLE
    NSC-38608
    THIAMAZOLE
    FAVISTAN
    MERCAZOLYL
    1-METHYLIMIDAZOLE-2(3H)-THIONE
    STRUMAZOL
    THACAPZOL
    USAF EL-30
    DANANTIZOL
    THIAMAZOL
    THIAMAZOLE®
    TIAMAZOL
    TAPAZOLE®
    THIAMAZOLUM
    1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE
    pubchem.compound:1349907
    chemidplus:60-56-0
    rxcui:6835
    chembl:CHEMBL1515
    drugbank:00763

    Drug Info:

    Year of Approval 1950
    Drug Class antithyroid agents
    FDA Approval 1950
    Drug Class small molecule
    Drug Indications Antithyroid Agents
    (4 More Sources)

    Publications:

    Vámos et al., 1997, [Bone metabolism markers in patients with Basedow-Graves disease]., Orv Hetil
    Bossowski et al., 2001, Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter., J. Pediatr. Endocrinol. Metab.
    Leonhardt et al., 1999, Immunoreactive leptin and leptin mRNA expression are increased in rat hypo- but not hyperthyroidism., J. Endocrinol.
    Wong et al., 2001, Effects of neonatal hypothyroidism on the expressions of growth cone proteins and axon guidance molecules related genes in the hippocampus., Mol. Cell. Endocrinol.
    Elias et al., 1993, Effect of propylthiouracil and methimazole on serum levels of interleukin-2 receptors in patients with psoriasis., Int. J. Dermatol.
    Gessl et al., 1995, Activated naive CD4+ peripheral blood T cells in autoimmune thyroid disease., Thyroid
    Balázs, 1991, Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease., Biomed. Pharmacother.
    Elias et al., 1995, Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in psoriatic lesions., Int. J. Dermatol.
    Liu, 1993, Expression of tumor necrosis factor and c-fos genes in peritoneal macrophages of hypothyroid mice., Inflammation
    Bossowski et al., 2003, Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease., Pediatr. Res.
    Ferreira et al., 2003, Thyroid Ca2+/NADPH-dependent H2O2 generation is partially inhibited by propylthiouracil and methimazole., Eur. J. Biochem.
    Chiovato et al., 1991, The microsomal/peroxidase antigen: modulation of its expression in thyroid cells., Autoimmunity
    Manzon et al., 2001, Variable effects of goitrogens in inducing precocious metamorphosis in sea lampreys (Petromyzon marinus)., J. Exp. Zool.
    Sugawara et al., 1999, Methimazole and propylthiouracil increase cellular thyroid peroxidase activity and thyroid peroxidase mRNA in cultured porcine thyroid follicles., Thyroid
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Magnusson et al., 1992, Effect of serum thyrotropin levels on the concentration of messenger RNA for thyroid peroxidase in the rat., Acta Endocrinol.
    Burch HB et al., 2018, ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later, Eur J Endocrinol
    Seoane et al., 1999, Degeneration and gliosis in rat retina and central nervous system following 3,3'-iminodipropionitrile exposure., Brain Res.
    Cheung CL et al., 2016, HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis., Clin Pharmacol Ther
    Chen PL et al., 2015, Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study., Nat Commun
    Bergman et al., 1999, Methimazole toxicity in rodents: covalent binding in the olfactory mucosa and detection of glial fibrillary acidic protein in the olfactory bulb., Toxicol. Appl. Pharmacol.
    Bossowski et al., 2004, [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy]., Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw
    Somogyi et al., 1996, Treatment of drug-induced bone marrow suppression with recombinant human granulocyte/monocyte colony stimulating factor., Adverse Drug React Toxicol Rev
    Somogyi et al., 1994, [Treatment of methimazole-induced agranulocytosis with granulocyte-macrophage colony stimulating factor]., Orv Hetil
  • METHIMAZOLE   TPO

    Interaction Score: 12.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)
    substrate

    Interaction Info:
    Mechanism of Interaction Thyroid peroxidase inhibitor
    Direct Interaction yes
    Trial Name -

    PMIDs:
    12755690 1663395 11241400 10365684 11752352 1320313 30320502


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • METHIMAZOLE   CRMP1

    Interaction Score: 6.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11694350


    Sources:
    NCI

  • METHIMAZOLE   DPYSL3

    Interaction Score: 6.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11694350


    Sources:
    NCI

  • METHIMAZOLE   CYP7B1

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10053173


    Sources:
    NCI

  • METHIMAZOLE   IL2RA

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8340196 7647571 1760523


    Sources:
    NCI

  • METHIMAZOLE   LEP

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10495413


    Sources:
    NCI

  • METHIMAZOLE   HLA-B

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26599303 26151496


    Sources:
    PharmGKB

  • METHIMAZOLE   CTLA4

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15504312


    Sources:
    NCI

  • METHIMAZOLE   FCGR3B

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12761360


    Sources:
    NCI

  • METHIMAZOLE   BGLAP

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9380378


    Sources:
    NCI

  • METHIMAZOLE   GFAP

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10375702


    Sources:
    NCI

  • METHIMAZOLE   CSF2

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8836317 7991239


    Sources:
    NCI

  • METHIMAZOLE   CXCL8

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11453524


    Sources:
    NCI

  • METHIMAZOLE   HLA-DRB1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • METHIMAZOLE   TNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8491516


    Sources:
    NCI

  • METHIMAZOLE   JUN

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHIMAZOLE   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7790147


    Sources:
    NCI

  • METHIMAZOLE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: METHIMAZOLE

    • Version: 01-August-2011

    Alternate Names:
    METHIMAZOLE Primary Drug Name

    Drug Info:
    Drug Class antithyroid agents
    Year of Approval 1950

    Publications:

  • TdgClinicalTrial: METHIMAZOLE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antithyroid Agents
    Drug Class small molecule
    FDA Approval 1950

    Publications:

  • NCI: METHIMAZOLE

    • Version: 14-September-2017

    Alternate Names:
    C641 NCI drug code

    Drug Info:

    Publications:
    Vámos et al., 1997, [Bone metabolism markers in patients with Basedow-Graves disease]., Orv Hetil
    Bossowski et al., 2001, Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter., J. Pediatr. Endocrinol. Metab.
    Leonhardt et al., 1999, Immunoreactive leptin and leptin mRNA expression are increased in rat hypo- but not hyperthyroidism., J. Endocrinol.

  • PharmGKB: methimazole

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Cheung CL et al., 2016, HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis., Clin Pharmacol Ther
    Chen PL et al., 2015, Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study., Nat Commun

  • TTD: Methimazole

    • Version: 2020.06.01

    Alternate Names:
    D0S4BR TTD Drug ID

    Drug Info:

    Publications:

  • DTC: METHIMAZOLE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1515 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1515

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1515

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21